DOCSLIB.ORG

Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status JASN Express. Published on July 16, 2009 as doi: 10.1681/ASN.2008111205 CLINICAL RESEARCH www.jasn.org Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status Ione de Brito-Ashurst, Mira Varagunam, Martin J. Raftery, and Muhammad M. Yaqoob Department of Renal Medicine and Transplantation, William Harvey Research Institute and Barts and the London NHS Trust, London, United Kingdom ABSTRACT Bicarbonate supplementation preserves renal function in experimental chronic kidney disease (CKD), but whether the same benefit occurs in humans is unknown. Here, we randomly assigned 134 adult patients with CKD (creatinine clearance [CrCl] 15 to 30 ml/min per 1.73 m2) and serum bicarbonate 16 to 20 mmol/L to either supplementation with oral sodium bicarbonate or standard care for 2 yr. The primary end points were rate of CrCl decline, the proportion of patients with rapid decline of CrCl (Ͼ3 ml/min per 1.73 m2/yr), and ESRD (CrCl Ͻ10 ml/min). Secondary end points were dietary protein intake, normalized protein nitrogen appearance, serum albumin, and mid-arm muscle circumference. Compared with the control group, decline in CrCl was slower with bicarbonate supplementation (5.93 versus 1.88 ml/min 1.73 m2; P Ͻ 0.0001). Patients supplemented with bicarbonate were significantly less likely to experience rapid progression (9 versus 45%; relative risk 0.15; 95% confidence interval 0.06 to 0.40; P Ͻ 0.0001). Similarly, fewer patients supplemented with bicarbonate developed ESRD (6.5 versus 33%; relative risk 0.13; 95% confidence interval 0.04 to 0.40; P Ͻ 0.001). Nutritional parameters improved significantly with bicarbonate supplementation, which was well tolerated. This study demonstrates that bicarbonate supplementation slows the rate of progression of renal failure to ESRD and improves nutritional status among patients with CKD. J Am Soc Nephrol ●●: –, 2009. doi: 10.1681/ASN.2008111205 Metabolic acidosis (MA), generally perceived by albumin, a reduction in normalized protein cata- Ϫ 8–10 clinicians as a low plasma bicarbonate (HCO3 ), is bolic rate, and an increase in the concentrations a common complication in patients with advanced of total essential amino acids.11,12 chronic kidney disease (CKD), particularly when Evidence implicating MA in the progression of GFR falls below 30 ml/min.1 This, in turn, may renal failure in patients with CKD is less convinc- bring about a variety of sequelae, such as stunted ing. Some experimental studies in rats have indi- growth in children, loss of bone and muscle mass, cated that the MA of CKD is associated with the negative nitrogen balance, and possible accelera- development and worsening of proteinuria and tu- tion of progression of CKD.2 There is good experi- mental but limited clinical evidence that MA con- Received November 24, 2008. Accepted May 18, 2009. tributes to protein-energy wasting (PEW) disorder 3 Published online ahead of print. Publication date available at in patients with CKD. Acidosis is associated with www.jasn.org. increased protein catabolism4 as a result of upregu- 5 This study is registered on the International Standard Random- lation of the ubiquitin-proteasome system, exces- ized Controlled Trial Number Registry (ISRCTN-17109689). sive oxidation of branched-chain amino acids,6 and Correspondence: Prof. Muhammad M. Yaqoob, Department of reduced synthesis of visceral proteins including al- Renal Medicine and Transplantation, Royal London Hospital, bumin.7 Several small, short-term clinical trials, Whitechapel, London E1 1BB UK. Phone: ϩ442073777236; Fax: mainly of dialysis patients, suggested that correc- ϩ442073777003; E-mail: [email protected] tion of acidosis is associated with increased serum Copyright ᮊ 2009 by the American Society of Nephrology J Am Soc Nephrol ●●: –, 2009 ISSN : 1046-6673/●●00- 1 CLINICAL RESEARCH www.jasn.org RESULTS During a 1-yr period, 184 incident patients Ϫ with CKD and low plasma HCO3 were seen. Fifty patients were excluded: 20 refused con- sent, and 30 were ineligible because of exclu- sion criteria (steroid therapy, n ϭ 4; congestive heart failure, n ϭ 7; uncontrolled hyperten- sion, n ϭ 11; cognitive impairment, n ϭ 3; on- going sepsis, n ϭ 2; and morbid obesity, n ϭ 3). A total of 134 patients were recruited. After re- cruitment and randomization, five patients from the treatment group withdrew before re- ceiving any study drug because three were transferred to another affiliated renal unit and two were unwilling to perform the 24-h urine collections every 2 mo (Figure 1). Their 6-monthly data were included for an intention- to-treat analysis. Demographic characteristics were similar for both groups (Table 1). There were no significant differences in any baseline clinical or nutritional parameters between the two groups (Table 2). Oral sodium bicarbonate supplementation was given at a dosage of 1.82 Ϯ 0.80 g/d, Figure 1. Participant enrollment and randomization to the study. Arm A (left whereas the control group received standard column) allocated to oral bicarbonate and arm B (right colum) allocated to Ϫ standard therapy. treatment. Serum HCO3 levels increased sig- nificantly in the treatment group compared bulointerstitial fibrosis and acceleration in the rate of decline with the control group and was maintained throughout the in renal function13–16; however, other studies have failed to study period (P Ͻ 0.001; Figure 2A). This was achieved at confirm this effect. Rats with CKD produced by the 5/6 ne- the expense of an increased sodium intake, as shown by phrectomy model failed to demonstrate a beneficial effect of 17 sodium bicarbonate supplementation. In rats that had CKD Table 1. Baseline demographic characteristics of patientsa and were receiving a high-phosphate diet, MA actually pre- Variable Control Bicarbonate vented progression of renal failure, presumably as a result of inhibition of calcium phosphate deposition in the kidney.18,19 Demographic Ϯ Ϯ Ϯ Few studies have examined the effects of amelioration of MA age (yr; mean SE) 54.77 2.34 54.78 2.56 on renal function in humans. In short-term studies, adminis- male (%) 51 52 white (%) 52 52 tration of oral sodium bicarbonate to patients with moderate black/Asian (%) 48 48 renal failure led to reduced protein catabolism, reduced am- Diagnosis (%) monia production, and tubular damage, as assessed by bio- diabetes 36 37 20 chemical parameters. Because of the short-term follow-up, hypertension 26 29 no substantial impact on renal function could be demonstrat- CRF unknown 14 10 ed; however, in one cohort study,21 MA was independently glomerulonephritis 13 10 associated with acceleration of renal failure in patients with obstructive uropathy 4 1 CKD. The lack of long-term studies examining the impact of other 7 12 alleviation of MA on renal function in predialysis patients and Medications (%) on nutritional status was the particular stimulus to perform loop diuretics 67 70 this study. We proposed the hypothesis that oral bicarbonate moxonodine 15 17 Ϫ ␣ blockers 57 59 supplementation in patients with acidosis (plasma HCO3 ␤ Ͼ Ͻ blockers 17 19 levels 16 and 20 mmol/L) would be associated with atten- calcium channel 48 50 uation of the rate of decline of creatinine clearance (CrCl) and blockers a reduction in number of patients with rapid progression of ACEIs/ARBs 48 50 renal failure defined arbitrarily as an annual fall in CrCl Ͼ3 allopurinol 3 0 2 ml/min per 1.73 m . aCRF, chronic renal failure. 2 Journal of the American Society of Nephrology J Am Soc Nephrol ●●: –, 2009 www.jasn.org CLINICAL RESEARCH Table 2. Baseline characteristics of the study populationa increased urinary sodium excretion in the Variable Control Bicarbonate P treatment group compared with control Ͻ Weight (kg) 74.9 Ϯ 11.5 76.6 Ϯ 21.1 0.84 patients (P 0.05; Figure 2B). Systolic BP (mmHg) 123.7 Ϯ 1.2 124.0 Ϯ 1.3 0.84 Despite increased sodium intake, BP Diastolic BP (mmHg) 75.4 Ϯ 1.9 76.1 Ϯ 1.5 0.91 control was similar between the groups MAMC (cm) 24.8 Ϯ 2.4 24.6 Ϯ 2.9 0.81 (Figure 2C). The number of patients with Albumin (g/L) 35.1 Ϯ 0.8 34.7 Ϯ 0.5 0.76 BP of Ͼ130/80 mmHg was 14 and 10 at Bicarbonate (mmol/L) 19.9 Ϯ 1.5 19.8 Ϯ 2.2 0.66 baseline, 15 and 16 at 12 mo, and 16 and 17 CrCl (ml/min per 1.73 m2) 20.70 Ϯ 5.55 20.12 Ϯ 6.47 0.60 at the end of the study in the control and Urinary Na (mmol/L) 140.1 Ϯ 4.4 140.0 Ϯ 7.9 0.96 bicarbonate groups, respectively. Through- Ϯ Ϯ Urinary protein (g/24 h) 1.8 0.2 1.7 0.8 0.84 out the study period, the proportion of pa- a Ϯ Data are means SE. tients in both groups with BP of Ͼ130/80 mmHg was not statistically significant (P ϭ 0.60). There was no difference in the num- Ϫ Figure 2. (A) Plasma HCO3 levels during the study period. Squares and bars denote means and SD. (B) Urinary sodium (Na) excretion per day. Squares and bars denote means and SD. (C) BP control during the study period. Squares and bars denote means and SD. (D) Urinary total protein excretion per day during the study period. Squares and bars denote means and SD. (E) Rate of decline of CrCl. Squares and bars denote means and SD. J Am Soc Nephrol ●●: –, 2009 Bicarbonate and Progression of CKD 3 CLINICAL RESEARCH www.jasn.org Table 3. Adverse events during the study perioda Control (% of Bicarbonate (% of Adverse Events P Patients) Patients) Hospitalization for CHF 0 0 N/A Worsening hypertension requiring increase in therapy 48 61 0.17 Worsening edema requiring increase in loop diuretics 30 39 0.5 Bad taste requiring switch to powder form of sodium bicarbonate N/A 6.5 N/A aCHF, congestive heart failure.
Load more

Recommended publications
  • The Effect of Calcium Carbonate and Sodium Bicarbonate on the Toxicity of Gossypol»
    THE EFFECT OF CALCIUM CARBONATE AND SODIUM BICARBONATE ON THE TOXICITY OF GOSSYPOL» By WILLIS D. GALLUP, assistant chemist, and RUTH REDER, associate chemist, Department of Agricultural Chemistry Research, Oklahoma Agricultural Experi- ment Station INTRODUCTION In a previous study of the influence of certain dietary constituents on the response of rats to gossypol ingestion {2) ^ the authors showed that the toxicity of diets containing known amounts of gossypol was materially reduced when the diets were made basic by the addition of calcium carbonate and sodium bicarbonate. When the diets were made acidic by the addition of calcium chloride, only indirect evidence of a slight decrease in toxicity was obtained. Decreased toxicity was observed also when the protein content of the diet was increased from 13 percent to 35 percent. The conclusion was drawn that diets of high protein content and basic diets of high calcium content are favorable to the detoxication of gossypol. Considerable importance is attached to the results since calcium and protein are variable ingredients in diets used for the bio-assay of gossypol. The importance of these constituents in feeding cottonseed products to livestock has not been fully determined, although the value of supplementary protein in cottonseed-meal rations for pigs has recently been pointed out by Robison (5). In view of the favorable results obtained with sodium bicarbonate and calcium carbonate, it was deemed desirable to determine the pro- portion of these salts which would offer the greatest degree of pro- tection against gossypol injury and to determine the value of each salt in the presence of moderate amounts of thç other, as the principal elements of both are requisite for a normal nutritive condition.
    [Show full text]
  • Experimental Study on Capture of Carbon Dioxide and Production of Sodium Bicarbonate from Sodium Hydroxide
    Environ. Eng. Res. 2016; 21(3): 297-303 pISSN 1226-1025 http://dx.doi.org/10.4491/eer.2016.042 eISSN 2005-968X Experimental study on capture of carbon dioxide and production of sodium bicarbonate from sodium hydroxide Jae-Goo Shim†, Dong Woog Lee, Ji Hyun Lee, No-Sang Kwak KEPCO Research Institute, 105 Munji-ro, Yuseong-gu, Daejeon, 54056, Korea ABSTRACT Global warming due to greenhouse gases is an issue of great concern today. Fossil fuel power plants, especially coal-fired thermal power plants, are a major source of carbon dioxide emission. In this work, carbon capture and utilization using sodium hydroxide was studied experimentally. Application for flue gas of a coal-fired power plant is considered. Carbon dioxide, reacting with an aqueous solution of sodium hydroxide, could be converted to sodium bicarbonate (NaHCO3). A bench-scale unit of a reactor system was designed for this experiment. The capture scale of the reactor system was 2 kg of carbon dioxide per day. The detailed operational condition could be determined. The purity of produced sodium bicarbonate was above 97% and the absorption rate of CO2 was above 95% through the experiment using this reactor system. The results obtained in this experiment contain useful information for the construction and operation of a commercial-scale plant. Through this experiment, the possibility of carbon capture for coal power plants using sodium hydroxide could be confirmed. Keywords: Carbon Capture, Carbon Utilization, Sodium Bicarbonate 1. Introduction the post-combustion amine process [8-11]. The amine process is has been a proven method for a relatively long time, and it is close to commercialization.
    [Show full text]
  • Laboratory Manual
    International Program UAM-Boston University Laboratory Manual Organic Chemistry I 2013-2014 Departamento de Química Orgánica Ernesto Brunet Romero Ana María Martín Castro Ramón Gómez Arrayás Laboratory Manual Table of Contents ............................................................................... 1 Introduction ............................................................................... 2 Prelab preparation ............................................................................... 2 Notebook ............................................................................. 3 Safety .............................................................................. 3 Laboratory Practices and Safety Rules ............................................................. 4 Accidents and injuries ........................................................................... 5 Fires ............................................................................. 5 Chemical Wastes ............................................................................. 6 Cleaning Responsibilities ............................................................................. 6 Lab cleanliness ............................................................................. 6 Laboratory Equipment ............................................................................. 7 Proper use of glassware ............................................................................. 8 Some techniques in lab experiments Heating, cooling and stirring ............................................................................
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Experimental Study on Capture of Carbon Dioxide and Production of Sodium Bicarbonate from Sodium Hydroxide
    Environ. Eng. Res. 2016 Research Article http://dx.doi.org/10.4491/eer.2016.042 pISSN 1226-1025 eISSN 2005-968X In Press, Uncorrected Proof Experimental study on capture of carbon dioxide and production of sodium bicarbonate from sodium hydroxide † Jae-Goo Shim , Dong Woog Lee, Ji Hyun Lee, No-Sang Kwak KEPCO Research Institute, 105 Munji-ro, Yuseong-gu, Daejeon, 54056, Korea Abstract Global warming due to greenhouse gases is an issue of great concern today. Fossil fuel power plants, especially coal-fired thermal power plants, are a major source of carbon dioxide emission. In this work, carbon capture and utilization using sodium hydroxide was studied experimentally. Application for flue gas of a coal-fired power plant is considered. Carbon dioxide, reacting with an aqueous solution of sodium hydroxide, could be converted to sodium bicarbonate (NaHCO3). A bench-scale unit of a reactor system was designed for this experiment. The capture scale of the reactor system was 2 kg of carbon dioxide per day. The detailed operational condition could be determined. The purity of produced sodium bicarbonate was above 97% and the absorption rate of CO2 was above 95% through the experiment using this reactor system. The results obtained in this experiment contain useful information for the construction and operation of a commercial-scale plant. Through this experiment, the possibility of carbon capture for coal power plants using sodium hydroxide could be confirmed. This is an Open Access article distributed under the terms Received March 14, 2016 Accepted May 10, 2016 of the Creative Commons Attribution Non-Commercial Li- † cense (http://creativecommons.org/licenses/by-nc/3.0/) Corresponding Author which permits unrestricted non-commercial use, distribution, and repro- E-mail: [email protected] duction in any medium, provided the original work is properly cited.
    [Show full text]
  • Acids and Bases Experiments (Organic Classes)
    Acids and Bases Experiments (Organic Classes) NaHCO3 (sodium bicarbonate, baking soda) and vinegar (dilute acetic acid) will be used to shoot a cork out of a bottle to show that some acid-base reactions generate gases like CO2. All students in the class will participate in a voice-activated chemical reaction. Students will remove a stopper and speak into a flask containing base and an indicator that will change color once enough CO2 is introduced from the students’ breath. Further color changes from basic to acidic conditions are illustrated using natural and household liquids and a universal indicator prepared from red cabbage juice. Finally, conversion between colorless and colored forms of different acid-base indicators in unusual settings will be shown in the “invisible painting” experiment. Supplies Needed: For the rocket reaction: You provide the following items indicated in red and starred: * empty 1 L plastic soda bottle with label removed * vinegar (colorless) Plastic powder funnel (we provide) cork with streamers attached by a thumbtack (we provide) container of de-ionized water (we provide, you refill as needed) sodium bicarbonate (we provide, return unused) Please clean and return all materials For the voice-activated chemical reaction: water that we provide as 250 mL Erlenmeyer flask (we provide)) soon as possible. dropper bottle with colorless phenolphtalein indicator (we provide) Other students may small amount of 1 M NaOH solution (we provide) need to use this “kit” disposable plastic droppers (we provide) for their ChemDemo!! For the universal pH indicator from red cabbage: * Red cabbage juice (you make the day before the demo) * 1 lemon, 1 soap bar, Sprite, vinegar, drain cleaner * 7 stirring rods (e.g.
    [Show full text]
  • Nitroxyl (Hno) and Carbonylnitrenes
    INVESTIGATION OF REACTIVE INTERMEDIATES: NITROXYL (HNO) AND CARBONYLNITRENES by Tyler A. Chavez A dissertation submitted to the Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland February 2016 © 2016 Tyler A. Chavez All rights reserved Abstract Membrane inlet mass spectrometry (MIMS) is a well-established method used to detect gases dissolved in solution through the use of a semipermeable hydrophobic membrane that allows the dissolved gases, but not the liquid phase, to enter a mass spectrometer. Interest in the unique biological activity of azanone (nitroxyl, HNO) has highlighted the need for new sensitive and direct detection methods. Recently, MIMS has been shown to be a viable method for HNO detection with nanomolar sensitivity under physiologically relevant conditions (Chapter 2). In addition, this technique has been used to explore potential biological pathways to HNO production (Chapter 3). Nitrenes are reactive intermediates containing neutral, monovalent nitrogen atoms. In contrast to alky- and arylnitrenes, carbonylnitrenes are typically ground state singlets. In joint synthesis, anion photoelectron spectroscopic, and computational work we studied the three nitrenes, benzoylnitrene, acetylnitrene, and trifluoroacetylnitrene, with the purpose of determining the singlet-triplet splitting (ΔEST = ES – ET) in each case (Chapter 7). Further, triplet ethoxycarbonylnitrene and triplet t-butyloxycarbonylnitrene have been observed following photolysis of sulfilimine precursors by time-resolved infrared (TRIR) spectroscopy (Chapter 6). The observed growth kinetics of nitrene products suggest a contribution from both the triplet and singlet nitrene, with the contribution from the singlet becoming more prevalent in polar solvents. Advisor: Professor John P. Toscano Readers: Professor Kenneth D.
    [Show full text]
  • Pharmaceutical Compounding and Dispensing Sample Chapter
    Copyright Pharmaceutical Press www.pharmpress.com 6 Solutions Introduction and overview 101 Gargles and mouthwashes 105 General principles of solution preparation 103 Enemas and douches 105 Solubility 103 External solutions 105 Stability 103 Lotions 105 General method 103 Liniments 105 Oral solutions 104 Applications 105 Elixirs 104 Collodions 106 Linctuses 105 Worked examples 106 Syrups 105 Summary of essential principles relating to solutions 112 Mixtures 105 Packaging 112 Draughts 105 Discard dates 112 Spirits 105 Labelling 113 Paediatric drops 105 Introduction and overview Essentially a solution is a homogeneous liquid preparation that contains one or more dissolved med- Solutions are one of the oldest dosage forms used in the icaments. Since, by definition, active ingredients are treatment of patients and afford rapid and high dissolved within the vehicle, uniform doses by volume absorption of soluble medicinal products. Therefore, may be obtained without any need to shake the for- the compounding of solutions retains an important mulation. This is an advantage over some other for- place in therapeutics today. Owing to the simplicity mulation types (e.g. suspensions, see Chapter 7). and hence the speed of preparation of an ad hoc for- In general, water is chosen as the vehicle in which mulation, they are of particular use for individuals medicaments are dissolved, as it is non-toxic, non- who have difficulty in swallowing solid dosage forms irritant, tasteless, relatively cheap, and many drugs (for example paediatric, geriatric, intensive care and are water soluble. Problems may be encountered psychiatric patients), where compliance needs to be where active drugs are not particularly water soluble checked on administration (for example in prisons or or suffer from hydrolysis in aqueous solution.
    [Show full text]
  • Exothermic and Endothermic Reactions
    Name:_________________________________ Date:______________ Exothermic and Endothermic Reactions Question to Investigate Does the temperature increase, decrease, or stay the same in the reaction between baking soda and vinegar? Materials • 50 ml of vinegar • 1 teaspoon of baking soda • Thermometer Procedure 1. Place the thermometer in vinegar. Record the temperature on the activity sheet 2. While the thermometer is in the cup, add all of the baking soda from your cup. 3. Watch the thermometer to observe any change in temperature. Record the temperature after it has stopped changing. Question to Investigate Does the temperature increase, decrease, or stay the same in the reaction between baking soda solution and calcium chloride? Materials • Baking soda solution (Dissolve a teaspoon of baking soda in 50ml of water) • 1 teaspoon of Calcium chloride • Thermometer Procedure 1. Place the thermometer in the baking soda solution. Read the thermometer and record the temperature on the activity sheet. 2. While the thermometer is in the cup, add all of the calcium chloride from the cup. 3. Watch the thermometer to observe any change in temperature. Record the temperature when it stops changing. Name:_________________________________ Date:______________ Reaction A- Baking Soda and Vinegar Reactants Products Equation: Make a prediction. Do you think the reaction will be endothermic or exothermic? How will you know? _______________________________________________________________________ _______________________________________________________________________ Original temperature of liquid:________________ Temperature after baking soda was added: _______________ Change in temperature:__________________ 1. What happened to the temperature of the liquid in reaction A? ___________________________________ 2. Because the temperature _____________, it proves that the reaction _______________ heat and is therefore an __________________________ reaction 3.
    [Show full text]
  • United States Patent Office Patiented July 5, 1960
    2,944,061 United States Patent Office Patiented July 5, 1960 1. 2 sponding alcohols (X=H) by known methods of esteri 2,944,061 fication, in particular, by the action of an acid chloride in the presence of pyridine. CERTAIN INTRO MDAZOLEALKANOLS AND By the words “known methods” as used in this specifi ACYL DERVATIVES AND PROCESS cation and accompanying claims is meant methods hereto Robert Michel Jacob, Ablon-sur-Seine, Gilbert Louis fore employed or described in the chemical literature. Regnier, Paris, and Corne Crisan, Sceaux, France, The imidazole derivatives of the aforesaid formula pos assignors to Societe des Usines Chimiques Rhone sess valuable chemotherapeutic properties; in particular, Poulenc, Paris, France, a French body corporate they have utility in the treatment of infections due to path O ogenic protozoa such as certain species of amoebae (for No Drawing. Filled Jan. 8, 1959, Ser. No. 785,577 example Endamoeba histolytica) or trichomonas (for ex Claims priority, application France Sept. 20, 1957 ample Trichomonas vaginalis). They have a very low toxicity. 8 Claims. (C. 260-309) For therapeutic purposes, the new imidazoles are pref This invention relates to new imidazole derivatives and 5 erably employed as such or in the form of acid addition processes for their preparation. It is a continuation-in salts containing anions which are relatively innocuous part of application Serial No. 731,108, filed April 28, to the animal organism in therapeutic doses of the salts 1958, now abandoned. (such as hydrochlorides and other hydrohalides, phos According to the present invention there are provided phates, nitrates, sulphates, maleates, fumarates, citrates, 20 tartrates, methanesulphonates and ethanedisulphonates) new imidazoles conforming to the general formula: so that the beneficial physiological properties inherent in S the bases are not vitiated by side-effects ascribable to the C-R.
    [Show full text]
  • Lesson 3 Forming a Precipitate TEACHER GUIDE
    Lesson 3 Forming a precipitate TEACHER GUIDE Lesson summary Students meet chemist Adriana Garcia, who is a chemist at a wastewater treatment plant in Lima, Peru. She explains that one of the challenges of cleaning water is removing particles that are so small they do not settle or get caught in the filters. The best way to solve this problem is to use a chemical reaction that forms a precipitate, which is large enough to settle or get caught in the filters. Students combine two clear colorless solutions and get a white precipitate, which they filter. The products of this chemical reaction are chalk, salt, and water, which are recognizable and noticeably different from the reactants. This lesson will take two class periods. You will begin with a demonstration, and then students will conduct a chemical reaction that forms a precipitate. The precipitate will need to filter slowly and then dry overnight. On the first day, while students wait for the products to dry, introduce the chemical equation for this reaction. Students will be able to recognize all of the products. On the second day, students compare the precipitate to the reactants to find that it is truly a different substance with different properties. Key concepts + Formation of a precipitate is a clue that a chemical reaction may have occurred. + A precipitate is a solid that forms in the chemical reaction between liquids. It does not dissolve in the resulting solution. + The products of a chemical reaction are different from the reactants, but are made of the same type and number of atoms.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,534,962 Marschner (45) Date of Patent: Aug
    United States Patent (19) 11 Patent Number: 4,534,962 Marschner (45) Date of Patent: Aug. 13, 1985 (54) SODIUM BICARBONATE SUSPENSIONAS DEODORANT PRODUCT OTHER PUBLICATIONS 75 Inventor: Frank W. Marschner, Whitehouse Pharmaceutical Formulas, 1947, vol. II, p. 152, Station, N.J. Martindale, The Extra Pharmacopoeia, pp. 1705-1708, 1972. 73) Assignee: Colgate-Palmolive Company, New Amer. Perfumes & Cosmetics, 10/1963, vol. 78, pp. York, N.Y. 95-97. 21 Appl. No.: 423,952 Ash, A Formulary of Cosmetic Preparations, 1977, pp. 6, 11, 13, 14, 20, 24 and 25. 22 Filed: Sep. 27, 1982 Primary Examiner-Dale R. Ore Related U.S. Application Data Attorney, Agent, or Firm-Herbert S. Sylvester; Murray M. Grill; Norman Blumenkopf 63 Continuation of Ser. No. 221,093, Dec. 29, 1980, aban doned. 57 ABSTRACT 51) Int. C. ........................ A61K 7/32; A61K 47/00 A novel stable pituitous bicarbonate suspension in an 52 U.S. C. ...................................... 424/65; 514/770; aqueous/alcoholic medium having a high alcohol con 514/781 tent and a low water content, with substantially no 58) Field of Search .......................................... 424/65 bicarbonate in solution, containing hydroxyethyl cellu lose as the essential suspending agent, said alcohol con 56) References Cited tent exceeding the upper solubility of hydroxyethyl U.S. PATENT DOCUMENTS cellulose in said alcohol and the water content being 74,871 2/1868 Wilson .................................. 424/65 sufficient to prevent precipitation of said suspending 279,195 6/1883 Ilocomb ................................ 424/65 agent and at least 5% by weight; having utility in de 1,558,405 10/1925 Smith .................................... 424/65 odorant products such as roll-ons, pumps and on sub 2,145,583 1/1939 Carlson ............................
    [Show full text]